[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CL2013002219A1 - Composicion inmunogena que comprende bordetella bronchiseptica y un antigeno de pertactina aislado; y su uso para tratar o prevenir la infeccion por un patogeno respiratorio canino en un perro. - Google Patents

Composicion inmunogena que comprende bordetella bronchiseptica y un antigeno de pertactina aislado; y su uso para tratar o prevenir la infeccion por un patogeno respiratorio canino en un perro.

Info

Publication number
CL2013002219A1
CL2013002219A1 CL2013002219A CL2013002219A CL2013002219A1 CL 2013002219 A1 CL2013002219 A1 CL 2013002219A1 CL 2013002219 A CL2013002219 A CL 2013002219A CL 2013002219 A CL2013002219 A CL 2013002219A CL 2013002219 A1 CL2013002219 A1 CL 2013002219A1
Authority
CL
Chile
Prior art keywords
dog
treat
bordetella bronchiseptica
immunogenic composition
respiratory pathogen
Prior art date
Application number
CL2013002219A
Other languages
English (en)
Inventor
Omar Yousif Abdelmagid
Joseph Michael Bricker
Shelly Lynn Shields
Jeffrey E Galvin
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of CL2013002219A1 publication Critical patent/CL2013002219A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/098—Brucella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UNA COMPOSICIÓN INMUNÓGENA QUE COMPRENDE BORDETELLA BRONCHISEPTICA Y UN ANTÍGENO DE PERTACTINA AISLADO. UNA COMPOSICIÓN INMUNÓGENA QUE COMPRENDE UNA PLURALIDAD DE ANTÍGENOS DE PERTACTINA P68 RECOMBINANTES DONDE DICHA COMPOSICIÓN ESTÁ SUSTANCIALMENTE LIBRE DE AGREGADOS DE P68. USO DE DICHA COMPOSICIÓN INMUNÓGENA PORQUE SIRVE PARA PREPARAR UN MEDICAMENTO ÚTIL EN EL TRATAMIENTO O LA PREVENCIÓN DE LA INFECCIÓN POR UN PATÓGENO RESPIRATORIO CANINO EN UN PERRO.
CL2013002219A 2011-02-04 2013-08-02 Composicion inmunogena que comprende bordetella bronchiseptica y un antigeno de pertactina aislado; y su uso para tratar o prevenir la infeccion por un patogeno respiratorio canino en un perro. CL2013002219A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161439597P 2011-02-04 2011-02-04

Publications (1)

Publication Number Publication Date
CL2013002219A1 true CL2013002219A1 (es) 2014-01-31

Family

ID=45755432

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013002219A CL2013002219A1 (es) 2011-02-04 2013-08-02 Composicion inmunogena que comprende bordetella bronchiseptica y un antigeno de pertactina aislado; y su uso para tratar o prevenir la infeccion por un patogeno respiratorio canino en un perro.

Country Status (27)

Country Link
US (1) US20130302369A1 (es)
EP (2) EP2670432B1 (es)
JP (1) JP5833145B2 (es)
KR (1) KR101647180B1 (es)
CN (2) CN103561763A (es)
AU (2) AU2012213035A1 (es)
BR (1) BR112013019675B8 (es)
CA (1) CA2826060C (es)
CL (1) CL2013002219A1 (es)
CO (1) CO6791568A2 (es)
CY (1) CY1124093T1 (es)
DK (1) DK2670432T3 (es)
ES (1) ES2869175T3 (es)
HK (1) HK1245676A1 (es)
HR (1) HRP20210575T1 (es)
HU (1) HUE055669T2 (es)
LT (1) LT2670432T (es)
MX (1) MX347177B (es)
PL (1) PL2670432T3 (es)
PT (1) PT2670432T (es)
RS (1) RS61723B1 (es)
RU (1) RU2554480C2 (es)
SI (1) SI2670432T1 (es)
SM (1) SMT202100233T1 (es)
UA (2) UA110504C2 (es)
WO (1) WO2012104821A1 (es)
ZA (1) ZA201306615B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3311827T3 (da) 2011-10-03 2023-04-03 Canqura Oncology Ab Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærere for amfipatiske eller hydrofobe molekyler inden for det medicinske område, inklusiv cancerbehandling, samt fødevarerelaterede forbindelser
ES2748205T3 (es) * 2012-05-31 2020-03-13 Zoetis Services Llc Vacunación con coronavirus respiratorio canino para protección contra infecciones por B. Bronchiseptica
RU2730011C2 (ru) 2013-09-19 2020-08-14 Зоэтис Сервисиз Ллс Адъюванты на масляной основе
BR112016012127A2 (pt) * 2013-11-26 2017-09-26 Zoetis Services Llc composições para a indução da resposta imunológica
CN115317600A (zh) 2015-01-16 2022-11-11 硕腾服务有限责任公司 口蹄疫疫苗
EP3909971A1 (en) 2020-09-28 2021-11-17 Institute of Life Sciences (ILS) Whole cell livestock vaccine for respiratory diseases

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2571618A1 (fr) 1984-10-12 1986-04-18 Virbac Ctre Rech Biolog Nouveau vaccin contre la tracheobronchite infectieuse canine et son procede de preparation
US5019388A (en) * 1986-10-14 1991-05-28 Norden Laboratories Inc. Bordetella bronchiseptica vaccine
US4888169A (en) * 1986-10-14 1989-12-19 Norden Laboratories, Inc. Bordetella Bronchiseptica vaccine
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
PT1015026E (pt) * 1996-05-31 2006-08-31 Nat Univ Ireland Maynooth Il-12 como adjuvante para vacinas contra bordetella pertussis
RO120819B1 (ro) * 1996-07-02 2006-08-30 Connaught Laboratories Limited Vaccinuri dtp multivalente
EP1284993B1 (en) * 2000-05-25 2008-04-23 Institut Pasteur Polypeptides containing polymorphisms of the repeated regions of pertactin in bordetella pertussis, bordetella paraperussis and bordetella bronchiseptica. their use in diagnostics, and in immunogenic compositions
GB0217434D0 (en) * 2002-07-27 2002-09-04 Royal Vetinary College Biological material
WO2004067031A1 (en) 2003-01-29 2004-08-12 Pfizer Products Inc. Canine vaccines against bordetella bronchiseptica
US20050089533A1 (en) * 2003-01-29 2005-04-28 Joseph Frantz Canine vaccines against Bordetella bronchiseptica
GB0315323D0 (en) 2003-07-01 2003-08-06 Royal Veterinary College Vaccine composition
EP1667712B1 (en) * 2003-10-02 2010-07-21 GlaxoSmithKline Biologicals S.A. B. pertussis antigens and use thereof in vaccination
US7572620B2 (en) 2005-01-11 2009-08-11 Wisconsin Alumni Research Foundation H3 equine influenza A virus
EP1871410A2 (en) * 2005-04-07 2008-01-02 Pharmacia & Upjohn Company LLC Formulations and process for production of bordetella bronchiseptica p68 antigen and vaccines
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7384642B2 (en) 2005-08-25 2008-06-10 Merial Limited Canine influenza vaccines
BRPI0616328A2 (pt) * 2005-10-07 2011-06-14 Pfizer Prod Inc vacinas e mÉtodos para tratar influenza canino
US7468187B2 (en) 2005-10-18 2008-12-23 Iowa State University Research Foundation, Inc. Canine influenza virus and related compositions and methods of use
EP1941033A2 (en) * 2005-10-20 2008-07-09 Wyeth a Corporation of the State of Delaware Compositions and methods for the treatment of canine influenza virus disease
US7682619B2 (en) * 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
AU2007252296A1 (en) * 2006-05-19 2007-11-29 The Walter And Eliza Hall Institute Of Medical Research Immunogenic compositions

Also Published As

Publication number Publication date
UA110504C2 (ru) 2016-01-12
CN103561763A (zh) 2014-02-05
EP2670432B1 (en) 2021-03-17
HUE055669T2 (hu) 2021-12-28
KR20130118975A (ko) 2013-10-30
CO6791568A2 (es) 2013-11-14
CN107296955A (zh) 2017-10-27
NZ613759A (en) 2015-09-25
RU2013136151A (ru) 2015-03-10
AU2017203244B2 (en) 2019-05-09
HRP20210575T1 (hr) 2021-05-28
AU2012213035A1 (en) 2013-08-15
BR112013019675A2 (pt) 2017-01-31
PT2670432T (pt) 2021-05-04
EP3858381A1 (en) 2021-08-04
CA2826060A1 (en) 2012-08-09
PL2670432T3 (pl) 2021-10-11
JP2014504635A (ja) 2014-02-24
US20130302369A1 (en) 2013-11-14
JP5833145B2 (ja) 2015-12-16
HK1245676A1 (zh) 2018-08-31
MX2013009012A (es) 2013-12-06
SMT202100233T1 (it) 2021-05-07
MX347177B (es) 2017-04-17
ZA201306615B (en) 2015-04-29
CN107296955B (zh) 2021-11-23
BR112013019675B1 (pt) 2021-06-22
RS61723B1 (sr) 2021-05-31
DK2670432T3 (da) 2021-04-19
WO2012104821A1 (en) 2012-08-09
EP2670432A1 (en) 2013-12-11
SI2670432T1 (sl) 2021-08-31
CY1124093T1 (el) 2022-05-27
ES2869175T3 (es) 2021-10-25
AU2017203244A1 (en) 2017-06-08
BR112013019675B8 (pt) 2022-11-22
KR101647180B1 (ko) 2016-08-09
RU2554480C2 (ru) 2015-06-27
UA110505C2 (ru) 2016-01-12
CA2826060C (en) 2019-06-18
LT2670432T (lt) 2021-05-25

Similar Documents

Publication Publication Date Title
CL2013002219A1 (es) Composicion inmunogena que comprende bordetella bronchiseptica y un antigeno de pertactina aislado; y su uso para tratar o prevenir la infeccion por un patogeno respiratorio canino en un perro.
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
CL2008000445A1 (es) Metodo para la profilaxis y el tratamiento de una infeccion subclinica por circovirus porcino tipo 2 (pcv2) en un animal individual o un grupo de animales que comprende administrar un antigeno del pcv2; uso del antigeno pcv2 para la profilaxis de un
CO2017006580A2 (es) Anticuerpos humanos para hemaglutinina de influenza
CL2016000650A1 (es) Composicion de vacuna que comprende un antigeno y una formulacion coadyuvante, que comprende al menos el 50 % v/v de una fase oleosa, monofosforil-lipido a (mpl-a) o un analogo del mismo y un oligonucleotido inmunoestimulate; y uso de la composición de vacuna para preparar un medicamento.
EA201501033A1 (ru) Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
CL2015001756A1 (es) Compuestos derivados de carbamoilpiridona policiclicos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion de vih en un humano que tiene o se encuentra en riesgo de tener la infeccion.
AR056566A1 (es) Vacunas y procedimientos para tratar la gripe canina
CL2011002639A1 (es) Cepa bacteriana de mycoplasma bovis atenuada avirulenta; composicion inmunogenica que la comprende; y uso para fabricar un medicamento para infecciones producidas por m. bovis.
BRPI1006452A2 (pt) vacina ou composição imunogênica que é administrada após a exposição a indivíduos com infecção latente que previne a reativação de tuberculose; método para tratar um animal, incluindo o ser humano, contra a reativação da infecção por tuberculose causada por micobactérias virulentas, uso de um antígeno selecionado do grupo
UY32874A (es) Compuestos y composiciones como moduladores de la actividad de tlr
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
AR060565A1 (es) Vacuna para la gripe aviaria y metodos de uso
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
AR101740A1 (es) Terapia de combinación y composiciones
CL2011000877A1 (es) Composicion inmunogena para el tratamiento y/o profilaxis de ganado contra infecciones microbiologicas porque comprende antigeno de mycoplasma bovis; metodo de coadministracion de dos o mas antigenos a un ganado bovino.
EA201171032A1 (ru) Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
BR112017003462A2 (pt) coronavírus bovino atenuado, vacina, e, método de vacinação de um bovino.
PH12015501875A1 (en) Acellular pertussis vaccine
AR056712A1 (es) Composicion y vacuna efectiva para tratar prevenir o mejorar la inoculacion del virus de la influenza canina metodo pra generar un inmunogen del virus dela influenza equina o del virus de la influenza canina modelo de la inoculacion util para determinar la eficacia de la composicion contra el virus
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
CO2022012272A2 (es) Vacunas contra el coronavirus y métodos de uso
BR112016015078A2 (pt) método para prevenir ou tratar infecção por vírus influenza a h7n9, uso do anticorpo e composição farmacêutica
CO2020009043A2 (es) Anticuerpos humanos contra hemaglutinina de influenza
ECSP12011951A (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnóstico para una enfermedad parasitaria